Santarus Inc. Announces Presentation of New Open-Label UCERIS (Budesonide) Data at the Crohn's and Colitis Foundation of America Clinical & Research Conference

SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS) today announced that new data from a clinical study to assess the efficacy and safety of eight weeks of open-label treatment with the investigational drug UCERIS™ (budesonide) 9 mg Tablets in patients with mild or moderate active ulcerative colitis will be available in poster sessions on December 2–3, 2011 at the Crohn’s & Colitis Foundation’s Clinical & Research Conference, 2011 Advances in Inflammatory Bowel Diseases being held in Hollywood, Florida. The poster is titled Induction of Remission with Oral Budesonide MMX® (9 mg) Tablets in Patients with Active, Mild to Moderate Ulcerative Colitis: A Multicenter, Open-Label Efficacy and Safety Study (Travis, et al). The clinical study enrolled patients who failed to achieve clinical and endoscopic remission in a previous pivotal Phase III eight week induction study after receiving treatment in one of four treatment groups: UCERIS 9 mg, UCERIS 6 mg, Asacol® (mesalamine) 2400 mg, or placebo.

Back to news